摘要
Abstract
Objective To explore the effect of rosuvastatin on the progress of arteriosclerosis and cardiac function in patients with essential hypertension. Methods 178 clinic patients were randomly as signed to receive rosuvastatin (Astrazeneca) of 10 mg daily (91 patients, rosuvastatin group), or fluvastatin (Lescol) of 40 mg dialy (87 patients, fluvastatin group) for 8 months. Ultrasonography and cardiac function examinatin were performed and serum levels of matrix metalloproteinase (MMPs) and TNF-α, were detected before and after treatment. Results The baseline findings were similar in the two groups. After 8-month therapy, serum levels of total cholesterol, LDL, TNF-α, MMPs-2, and MMPs-9 were decreased and the intima media thickness of the common carotid artery and the plaque size in the coronary artery were declined in both groups, especially in rosuvastatin group (P<0.01 for all comparisons). LVPFR increased markedly in rosuvastatin group. LVEF and LVPFR were higher in rosuvastatin group than in fluvastatin group. Conclu sions Rosuvastatin therapy can relieve plaque formation and improve left ventricular function in patients with hyertension, whose mechanism may be involved in the decrease in serum levels of TNF-α, and MMPs.关键词
高血压/动脉粥样硬化/心功能/瑞舒伐他汀/氟伐他汀Key words
Hypertension/Arteriosclerosis/Cardiac function/Rosuvastatin/Fluvastatin
